# Arxx Therapeutics AS

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/arxx-therapeutics

- Industry: Biotechnology
- Headquarters: Oslo, Norway
- Website: http://www.arxxtx.com/
- Total disclosed funding: $13M
- Latest round: Seed (May 4, 2021)
- Investors on record: 10

## About

Based in Oslo, Norway, and founded in 2018 by co-founders Jorg Klingelhofer and Jonas Hallen, Arxx Therapeutics AS operates as a biopharmaceutical-based company providing medicine, drug development and molecular biology for patients suffering from fibrotic disease. In January 2024, Oxitope Pharma B.V. merged with Arxx Therapeutics AS, a portfolio company of Rasmussen Gruppen AS, Investinor, altitude Capital Management, Veen Eiendom AS, P53, Sarsia Management, Trond Mohn Stiftelsen, MP Pensjon, Asteroid Bakken AS and Andenes Investments, to form Calluna Pharma.

Arxx Therapeutics AS developed therapeutic strategies for Systemic sclerosis, which is an autoimmune disease that causes fibrosis and tissue dysfunction in human body organs. The company offers S100A4, that boosts the body and targets lesional tissue systemically in patients with SSc disease activity, skin fibrosis and pulmonary function. It created AX-202, which supports patients that ameliorate fibrosis in both inflammatory and non-inflammatory models of skin fibrosis.

## Funding rounds

- Seed, May 4, 2021, $13M — Sarsia, Investinor, Rasmussengruppen AS, MP Pensjon, Andenes Investments, p53, Altitude Capital Management, Veen Eiendom AS, Trond Mohn Stiftelsen, Asteroidebakken AS

## Investors

- Sarsia (https://capitalatlas.ai/funds/sarsia) — Seed
- Investinor (https://capitalatlas.ai/funds/investinor) — Seed
- Rasmussengruppen AS — Seed
- MP Pensjon — Seed
- Andenes Investments — Seed
- p53 (https://capitalatlas.ai/funds/p53) — Seed
- Altitude Capital Management (https://capitalatlas.ai/funds/altitude-capital-management) — Seed
- Veen Eiendom AS — Seed
- Trond Mohn Stiftelsen — Seed
- Asteroidebakken AS — Seed